| 1701 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
48 |
| 1702 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
52 |
| 1703 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
58 |
| 1704 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
61 |
| 1705 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
67 |
| 1706 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
71 |
| 1707 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
72 |
| 1708 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
63 |
| 1709 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
32 |
| 1710 |
Apheresis |
Autologous
|
Acute Myeloid Leukemia – Relapse
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
68 |
| 1711 |
Apheresis |
Allogeneic
|
Acute Myeloid Leukemia Relapse
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
33 |
| 1712 |
Apheresis |
Allogeneic
|
Amegakaryocytic/Congenital Thrombocytopenia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
63 |
| 1713 |
Apheresis |
Allogeneic
|
Anaplastic Large Cell Lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
52 |
| 1714 |
Apheresis |
Allogeneic
|
Angioimmunoblastic T-Cell Lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
47 |
| 1715 |
Apheresis |
Allogeneic
|
B-Cell Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
19 |
| 1716 |
Apheresis |
Allogeneic
|
B-Cell Non-Hodgkin Lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
62 |
| 1717 |
Apheresis |
Allogeneic
|
B-Cell Progenitor Acute Lymphoblastic Leukemia High Risk
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
4 |
| 1718 |
Apheresis |
Allogeneic
|
Calr Positive Myelofibrosis
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
61 |
| 1719 |
Apheresis |
Allogeneic
|
Chronic Lymphocytic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
60 |
| 1720 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukaemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
62 |
| 1721 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
10 |
| 1722 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
35 |
| 1723 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
42 |
| 1724 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
49 |
| 1725 |
Apheresis |
Allogeneic
|
Chronic Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
72 |
| 1726 |
Apheresis |
Allogeneic
|
Chronic Neutrophilic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
71 |
| 1727 |
Apheresis |
Allogeneic
|
Fanconi Aplastic Anemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
20 |
| 1728 |
Apheresis |
Allogeneic
|
Follicular Lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
48 |
| 1729 |
Apheresis |
Allogeneic
|
High Risk Acute Myeloid Leukaemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
15 |
| 1730 |
Apheresis |
Allogeneic
|
High Risk Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
69 |
| 1731 |
Apheresis |
Allogeneic
|
High-Risk Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
71 |
| 1732 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
27 |
| 1733 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
27 |
| 1734 |
Apheresis |
Allogeneic
|
Hodgkin Disease
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
28 |
| 1735 |
Apheresis |
Allogeneic
|
Hodgkin Lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
23 |
| 1736 |
Apheresis |
Allogeneic
|
Hypoplastic Myelodysplastic Syndrome/Acute Myelogenous Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
71 |
| 1737 |
Apheresis |
Allogeneic
|
Infant Acute Lymphoblastic Leukemia
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
41 |
| 1738 |
Apheresis |
Allogeneic
|
Kutanes T-Zell-Lymphom, Mycosis Fungoides
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
72 |
| 1739 |
Apheresis |
Autologous
|
Mantle Cell Lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
51 |
| 1740 |
Apheresis |
Autologous
|
Mantle Cell Lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
64 |
| 1741 |
Apheresis |
Autologous
|
Mantle Cell Lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
66 |
| 1742 |
Apheresis |
Autologous
|
Mantle Cell Lymphoma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
52 |
| 1743 |
Apheresis |
Autologous
|
Morbus Hodgkin
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
63 |
| 1744 |
Apheresis |
Allogeneic
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
43 |
| 1745 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
52 |
| 1746 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
54 |
| 1747 |
Apheresis |
Allogeneic
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
60 |
| 1748 |
Apheresis |
Allogeneic
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
61 |
| 1749 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
62 |
| 1750 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
62 |
| 1751 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
62 |
| 1752 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
62 |
| 1753 |
Apheresis |
Allogeneic
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
63 |
| 1754 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
64 |
| 1755 |
Apheresis |
Allogeneic
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
65 |
| 1756 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
65 |
| 1757 |
Apheresis |
Allogeneic
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
66 |
| 1758 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
66 |
| 1759 |
Apheresis |
Allogeneic
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
67 |
| 1760 |
Apheresis |
Allogeneic
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
68 |
| 1761 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
69 |
| 1762 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
70 |
| 1763 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
71 |
| 1764 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
72 |
| 1765 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
66 |
| 1766 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
62 |
| 1767 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
58 |
| 1768 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
61 |
| 1769 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
61 |
| 1770 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
62 |
| 1771 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
70 |
| 1772 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
74 |
| 1773 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
58 |
| 1774 |
Apheresis |
Autologous
|
Multiple Myeloma
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
63 |
| 1775 |
Apheresis |
Allogeneic
|
Myelodysplastic
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
68 |
| 1776 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
20 |
| 1777 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
22 |
| 1778 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
54 |
| 1779 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
58 |
| 1780 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
60 |
| 1781 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
62 |
| 1782 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
65 |
| 1783 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
67 |
| 1784 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
67 |
| 1785 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
67 |
| 1786 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
69 |
| 1787 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
69 |
| 1788 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
70 |
| 1789 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
71 |
| 1790 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
73 |
| 1791 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Germany
|
60 |
| 1792 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
53 |
| 1793 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
69 |
| 1794 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
59 |
| 1795 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
60 |
| 1796 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
49 |
| 1797 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
52 |
| 1798 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
63 |
| 1799 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
66 |
| 1800 |
Apheresis |
Allogeneic
|
Myelodysplastic Syndrome
|
Hematology
|
2024
|
Standard Therapy
|
Poland
|
58 |